Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Follicular Lymphoma Grade 3B: early-phase trial registry
1 of 3 indexed Follicular Lymphoma Grade 3B trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Follicular Lymphoma Grade 3B: 3 US clinical trials tracked, 1 recruiting.
Follicular Lymphoma Grade 3B is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Poseida Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition follicular-lymphoma-grade-3b
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Follicular Lymphoma Grade 3B lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Follicular Lymphoma Grade 3B on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Follicular Lymphoma Grade 3B is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics
NCT06014762
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Washington University School of Medicine
NCT05464329
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT04088890
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Follicular Lymphoma Grade 3B records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Follicular Lymphoma Grade 3B trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Follicular Lymphoma Grade 3B page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Follicular Lymphoma Grade 3B trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Poseida Therapeutics sponsors the most Follicular Lymphoma Grade 3B trials on record, review their full trial history before evaluating a specific study. See Poseida Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Follicular Lymphoma Grade 3B condition card totals 3 registered trials; most-linked intervention CD22 CAR; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.